Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma

Tatsuo Okui, Tsuyoshi Shimo, Takuya Fukazawa, Nur Mohammad Monsur Hassan, Tatsuki Honami, Soichiro Ibaragi, Munenori Takaoka, Yoshio Naomoto, Akira Sasaki

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background and Aim: Heat shock protein 90 (HSP90) and mammalian target of rapamycin (mTOR) are involved in the molecular pathogenesis of advanced oral squamous cell carcinoma. HSP90 inhibitors are capable of effectively interfering with multiple signaling pathways, including the mTOR signaling pathway. However, the combined effects of HSP90 and mTOR inhibitors on oral squamous cell carcinoma are still unknown. In this study, we investigated the dual treatment of the novel HSP90 inhibitor NVP-AUY922 and temsirolimus against oral squamous cell carcinoma. Materials and Methods: The effect of the combination of NVP-AUY922 and temsirolimus on oral squamous cell carcinoma in vitro and in vivo was determined by MTS assay and mouse xenograft models. The effect of the combination on angiogenesis was determined by tube formation assay and angioreactor. Results: The combination treatment of NVP-AUY922 and temsirolimus significantly inhibited the proliferation of SAS oral squamous cell carcinoma cells in vitro and suppressed the growth of oral squamous cell carcinoma xenografts in vivo. We have clearly shown that the combination treatment of NVP-AUY922 and temsirolimus inhibited vascular formation both in vitro and in vivo. Moreover, the combination treatment of NVP-AUY922 and temsirolimus prolonged the survival rate in mice xenografted with oral squamous cell carcinoma. Conclusions: Here, we showed the activity of a combination of mTOR and HSP90 inhibitors for the treatment of advanced oral squamous carcinoma.

Original languageEnglish
Pages (from-to)289-299
Number of pages11
JournalCurrent Cancer Drug Targets
Volume13
Issue number3
DOIs
Publication statusPublished - 2013

Fingerprint

HSP90 Heat-Shock Proteins
Squamous Cell Carcinoma
Sirolimus
Neoplasms
Heterografts
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
temsirolimus
Blood Vessels

Keywords

  • Angiogenesis
  • Combination treatment
  • HSP90 inhibitor
  • NVP-AUY922
  • Oral squamous cell carcinoma
  • Temsirolimus

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma. / Okui, Tatsuo; Shimo, Tsuyoshi; Fukazawa, Takuya; Hassan, Nur Mohammad Monsur; Honami, Tatsuki; Ibaragi, Soichiro; Takaoka, Munenori; Naomoto, Yoshio; Sasaki, Akira.

In: Current Cancer Drug Targets, Vol. 13, No. 3, 2013, p. 289-299.

Research output: Contribution to journalArticle

Okui, Tatsuo ; Shimo, Tsuyoshi ; Fukazawa, Takuya ; Hassan, Nur Mohammad Monsur ; Honami, Tatsuki ; Ibaragi, Soichiro ; Takaoka, Munenori ; Naomoto, Yoshio ; Sasaki, Akira. / Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma. In: Current Cancer Drug Targets. 2013 ; Vol. 13, No. 3. pp. 289-299.
@article{767b7e085efe4f6f858e5aae1848f40a,
title = "Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma",
abstract = "Background and Aim: Heat shock protein 90 (HSP90) and mammalian target of rapamycin (mTOR) are involved in the molecular pathogenesis of advanced oral squamous cell carcinoma. HSP90 inhibitors are capable of effectively interfering with multiple signaling pathways, including the mTOR signaling pathway. However, the combined effects of HSP90 and mTOR inhibitors on oral squamous cell carcinoma are still unknown. In this study, we investigated the dual treatment of the novel HSP90 inhibitor NVP-AUY922 and temsirolimus against oral squamous cell carcinoma. Materials and Methods: The effect of the combination of NVP-AUY922 and temsirolimus on oral squamous cell carcinoma in vitro and in vivo was determined by MTS assay and mouse xenograft models. The effect of the combination on angiogenesis was determined by tube formation assay and angioreactor. Results: The combination treatment of NVP-AUY922 and temsirolimus significantly inhibited the proliferation of SAS oral squamous cell carcinoma cells in vitro and suppressed the growth of oral squamous cell carcinoma xenografts in vivo. We have clearly shown that the combination treatment of NVP-AUY922 and temsirolimus inhibited vascular formation both in vitro and in vivo. Moreover, the combination treatment of NVP-AUY922 and temsirolimus prolonged the survival rate in mice xenografted with oral squamous cell carcinoma. Conclusions: Here, we showed the activity of a combination of mTOR and HSP90 inhibitors for the treatment of advanced oral squamous carcinoma.",
keywords = "Angiogenesis, Combination treatment, HSP90 inhibitor, NVP-AUY922, Oral squamous cell carcinoma, Temsirolimus",
author = "Tatsuo Okui and Tsuyoshi Shimo and Takuya Fukazawa and Hassan, {Nur Mohammad Monsur} and Tatsuki Honami and Soichiro Ibaragi and Munenori Takaoka and Yoshio Naomoto and Akira Sasaki",
year = "2013",
doi = "10.2174/1568009611313030007",
language = "English",
volume = "13",
pages = "289--299",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma

AU - Okui, Tatsuo

AU - Shimo, Tsuyoshi

AU - Fukazawa, Takuya

AU - Hassan, Nur Mohammad Monsur

AU - Honami, Tatsuki

AU - Ibaragi, Soichiro

AU - Takaoka, Munenori

AU - Naomoto, Yoshio

AU - Sasaki, Akira

PY - 2013

Y1 - 2013

N2 - Background and Aim: Heat shock protein 90 (HSP90) and mammalian target of rapamycin (mTOR) are involved in the molecular pathogenesis of advanced oral squamous cell carcinoma. HSP90 inhibitors are capable of effectively interfering with multiple signaling pathways, including the mTOR signaling pathway. However, the combined effects of HSP90 and mTOR inhibitors on oral squamous cell carcinoma are still unknown. In this study, we investigated the dual treatment of the novel HSP90 inhibitor NVP-AUY922 and temsirolimus against oral squamous cell carcinoma. Materials and Methods: The effect of the combination of NVP-AUY922 and temsirolimus on oral squamous cell carcinoma in vitro and in vivo was determined by MTS assay and mouse xenograft models. The effect of the combination on angiogenesis was determined by tube formation assay and angioreactor. Results: The combination treatment of NVP-AUY922 and temsirolimus significantly inhibited the proliferation of SAS oral squamous cell carcinoma cells in vitro and suppressed the growth of oral squamous cell carcinoma xenografts in vivo. We have clearly shown that the combination treatment of NVP-AUY922 and temsirolimus inhibited vascular formation both in vitro and in vivo. Moreover, the combination treatment of NVP-AUY922 and temsirolimus prolonged the survival rate in mice xenografted with oral squamous cell carcinoma. Conclusions: Here, we showed the activity of a combination of mTOR and HSP90 inhibitors for the treatment of advanced oral squamous carcinoma.

AB - Background and Aim: Heat shock protein 90 (HSP90) and mammalian target of rapamycin (mTOR) are involved in the molecular pathogenesis of advanced oral squamous cell carcinoma. HSP90 inhibitors are capable of effectively interfering with multiple signaling pathways, including the mTOR signaling pathway. However, the combined effects of HSP90 and mTOR inhibitors on oral squamous cell carcinoma are still unknown. In this study, we investigated the dual treatment of the novel HSP90 inhibitor NVP-AUY922 and temsirolimus against oral squamous cell carcinoma. Materials and Methods: The effect of the combination of NVP-AUY922 and temsirolimus on oral squamous cell carcinoma in vitro and in vivo was determined by MTS assay and mouse xenograft models. The effect of the combination on angiogenesis was determined by tube formation assay and angioreactor. Results: The combination treatment of NVP-AUY922 and temsirolimus significantly inhibited the proliferation of SAS oral squamous cell carcinoma cells in vitro and suppressed the growth of oral squamous cell carcinoma xenografts in vivo. We have clearly shown that the combination treatment of NVP-AUY922 and temsirolimus inhibited vascular formation both in vitro and in vivo. Moreover, the combination treatment of NVP-AUY922 and temsirolimus prolonged the survival rate in mice xenografted with oral squamous cell carcinoma. Conclusions: Here, we showed the activity of a combination of mTOR and HSP90 inhibitors for the treatment of advanced oral squamous carcinoma.

KW - Angiogenesis

KW - Combination treatment

KW - HSP90 inhibitor

KW - NVP-AUY922

KW - Oral squamous cell carcinoma

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84876852756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876852756&partnerID=8YFLogxK

U2 - 10.2174/1568009611313030007

DO - 10.2174/1568009611313030007

M3 - Article

VL - 13

SP - 289

EP - 299

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 3

ER -